GTCR's acquisition of Zentiva open for comments in EU
MLex Summary: Parties interested in plans by US private equity firm GTCR to buy generic drugmaker Zentiva have ten days to provide feedback to the European Commission. The EU merger regulator...To view the full article, register now.
Already a subscriber? Click here to view full article